PMID- 24300402
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20131204
LR  - 20231110
IS  - 1999-4923 (Print)
IS  - 1999-4923 (Electronic)
IS  - 1999-4923 (Linking)
VI  - 5
IP  - 1
DP  - 2013 Feb 8
TI  - From molecular to nanotechnology strategies for delivery of neurotrophins: 
      emphasis on brain-derived neurotrophic factor (BDNF).
PG  - 127-67
LID - 10.3390/pharmaceutics5010127 [doi]
AB  - Neurodegenerative diseases represent a major public health problem, but 
      beneficial clinical treatment with neurotrophic factors has not been established 
      yet. The therapeutic use of neurotrophins has been restrained by their 
      instability and rapid degradation in biological medium. A variety of strategies 
      has been proposed for the administration of these leading therapeutic candidates, 
      which are essential for the development, survival and function of human neurons. 
      In this review, we describe the existing approaches for delivery of brain-derived 
      neurotrophic factor (BDNF), which is the most abundant neurotrophin in the 
      mammalian central nervous system (CNS). Biomimetic peptides of BDNF have emerged 
      as a promising therapy against neurodegenerative disorders. Polymer-based 
      carriers have provided sustained neurotrophin delivery, whereas lipid-based 
      particles have contributed also to potentiation of the BDNF action. 
      Nanotechnology offers new possibilities for the design of vehicles for 
      neuroprotection and neuroregeneration. Recent developments in nanoscale carriers 
      for encapsulation and transport of BDNF are highlighted.
FAU - Geral, Claire
AU  - Geral C
AD  - CNRS UMR8612 Institut Galien Paris-Sud, 5 rue J.-B. Clement, F-92296 
      Chatenay-Malabry, France. Angelina.Angelova@u-psud.fr.
FAU - Angelova, Angelina
AU  - Angelova A
FAU - Lesieur, Sylviane
AU  - Lesieur S
LA  - eng
PT  - Journal Article
DEP - 20130208
PL  - Switzerland
TA  - Pharmaceutics
JT  - Pharmaceutics
JID - 101534003
PMC - PMC3834942
EDAT- 2013/12/05 06:00
MHDA- 2013/12/05 06:01
PMCR- 2013/03/01
CRDT- 2013/12/05 06:00
PHST- 2012/11/13 00:00 [received]
PHST- 2013/01/30 00:00 [revised]
PHST- 2013/02/05 00:00 [accepted]
PHST- 2013/12/05 06:00 [entrez]
PHST- 2013/12/05 06:00 [pubmed]
PHST- 2013/12/05 06:01 [medline]
PHST- 2013/03/01 00:00 [pmc-release]
AID - pharmaceutics5010127 [pii]
AID - pharmaceutics-05-00127 [pii]
AID - 10.3390/pharmaceutics5010127 [doi]
PST - epublish
SO  - Pharmaceutics. 2013 Feb 8;5(1):127-67. doi: 10.3390/pharmaceutics5010127.